BRIM Biotechnology, Inc.

Research BRIM Biotechnology, Inc. (6885.TW) on Bullrun: market cap TWD 4.47B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is TWD 4.47B.

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18TWD 4.47Bn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 TWD.

About BRIM Biotechnology, Inc.

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma;

Related stock research

Taiwan stocks Taiwan Healthcare stocks A-Z stock index

Other Healthcare stocks

Synbio Tech Inc. (1295.TWO) Sinphar Pharmaceutical Co.,Ltd. (1734.TW) Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) SYN-TECH Chem. & Pharm. Co., Ltd. (1777.TWO) Level Biotechnology Inc. (3118.TWO) GenMont Biotech Incorporation (3164.TW) Medigen Biotechnology Corp. (3176.TWO) Sagittarius Life Science Corp (3205.TWO) NeoCore Technology Co., Ltd. (4131.TWO) Abnova (Taiwan) Corporation (4133.TW) Adimmune Corporation (4142.TW) TaiMed Biologics Inc. (4147.TWO)

Frequently asked questions

What is BRIM Biotechnology, Inc.'s market cap?

BRIM Biotechnology, Inc.'s market capitalization is TWD 4.47B.

What does BRIM Biotechnology, Inc. do?

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease.